share_log
Reuters ·  Jan 28 12:00
Beyondspring Announces $35.4 Million Sale of a Portion of Equity Interest in Seed Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 363

Recommended

Write a comment